Ranibizumab, identified by its chemical formula Molecular Designation, represents a significant innovation in ophthalmology, acting as a highly selective antagonist of Vascular Endothelial Growth Factor A (VEGF-A). This https://www.targetmol.com/compound/ranibizumab